Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Parkinson's disease physiotherapy: specialisation adds value.

Parashos SA.

Lancet Neurol. 2018 Feb;17(2):108-109. doi: 10.1016/S1474-4422(17)30437-4. Epub 2017 Dec 12. No abstract available.

PMID:
29246469
2.

Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort.

Chou KL, Elm JJ, Wielinski CL, Simon DK, Aminoff MJ, Christine CW, Liang GS, Hauser RA, Sudarsky L, Umeh CC, Voss T, Juncos J, Fang JY, Boyd JT, Bodis-Wollner I, Mari Z, Morgan JC, Wills AM, Lee SL, Parashos SA; NINDS NET-PD Investigators.

J Neurol Sci. 2017 Jun 15;377:137-143. doi: 10.1016/j.jns.2017.04.011. Epub 2017 Apr 11.

3.

Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1.

Wills AA, Elm JJ, Ye R, Chou KL, Parashos SA, Hauser RA, Bodis-Wollner I, Hinson VK, Christine CW, Schneider JS; NINDS NET-PD Investigators.

Parkinsonism Relat Disord. 2016 Dec;33:127-133. doi: 10.1016/j.parkreldis.2016.10.005. Epub 2016 Oct 8.

PMID:
27743701
4.

Validation of an ambulatory capacity measure in Parkinson disease: a construct derived from the Unified Parkinson's Disease Rating Scale.

Parashos SA, Elm J, Boyd JT, Chou KL, Dai L, Mari Z, Morgan JC, Sudarsky L, Wielinski CL.

J Parkinsons Dis. 2015;5(1):67-73. doi: 10.3233/JPD-140405.

5.

Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.

Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators.

JAMA Neurol. 2014 Jun;71(6):710-6. doi: 10.1001/jamaneurol.2014.391.

6.

Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.

Parkinson Study Group SURE-PD Investigators, Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K.

JAMA Neurol. 2014 Feb;71(2):141-50. doi: 10.1001/jamaneurol.2013.5528.

7.

Mobility, mood and site of care impact health related quality of life in Parkinson's disease.

Nutt JG, Siderowf AD, Guttman M, Schmidt PN, Zamudio JI, Wu SS, Okun MS, Simuni T, Parashos SA, Dahodwala NA, Davis TL, Giladi N, Gurevich T, Hauser RA, Jankovic J, Lyons KE, Marsh L, Miyasaki JM, Morgan JC, Santiago AJ, Tarsy D, Mari Z, Malaty IA, Nelson EC; National Parkinson Foundation Quality Improvement Initiative Investigators.

Parkinsonism Relat Disord. 2014 Mar;20(3):274-9. doi: 10.1016/j.parkreldis.2013.10.004. Epub 2013 Oct 16.

PMID:
24182524
8.

Falls in Parkinson disease: analysis of a large cross-sectional cohort.

Parashos SA, Wielinski CL, Giladi N, Gurevich T; National Parkinson Foundation Quality Improvement Initiative Investigators.

J Parkinsons Dis. 2013;3(4):515-22. doi: 10.3233/JPD-130249.

PMID:
24113557
9.

Challenges of multidisciplinary care in Parkinson's disease.

Parashos SA.

Lancet Neurol. 2013 Oct;12(10):932-3. doi: 10.1016/S1474-4422(13)70145-5. Epub 2013 Aug 27. No abstract available.

PMID:
23988336
10.

Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers.

Chou KL, Zamudio J, Schmidt P, Price CC, Parashos SA, Bloem BR, Lyons KE, Christine CW, Pahwa R, Bodis-Wollner I, Oertel WH, Suchowersky O, Aminoff MJ, Malaty IA, Friedman JH, Okun MS.

Parkinsonism Relat Disord. 2011 Jul;17(6):440-5. doi: 10.1016/j.parkreldis.2011.03.002. Epub 2011 Apr 1.

11.

Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines.

Aminoff MJ, Christine CW, Friedman JH, Chou KL, Lyons KE, Pahwa R, Bloem BR, Parashos SA, Price CC, Malaty IA, Iansek R, Bodis-Wollner I, Suchowersky O, Oertel WH, Zamudio J, Oberdorf J, Schmidt P, Okun MS; National Parkinson Foundation Working Group on Hospitalization in Parkinson's Disease.

Parkinsonism Relat Disord. 2011 Mar;17(3):139-45. doi: 10.1016/j.parkreldis.2010.11.009. Epub 2010 Dec 14. Review.

12.

Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.

Schneider JS, Elm JJ, Parashos SA, Ravina BM, Galpern WR; NET-PD Investigators.

Parkinsonism Relat Disord. 2010 Sep;16(8):507-12. doi: 10.1016/j.parkreldis.2010.06.001. Epub 2010 Jul 2.

13.

Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.

Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R.

Clin Neuropharmacol. 2010 Jan-Feb;33(1):5-10. doi: 10.1097/WNF.0b013e3181b7926f.

PMID:
19855267
14.

Assessing cognition in Parkinson disease: use of the cognitive linguistic quick test.

Parashos SA, Johnson ML, Erickson-Davis C, Wielinski CL.

J Geriatr Psychiatry Neurol. 2009 Dec;22(4):228-34. doi: 10.1177/0891988709342721. Epub 2009 Aug 7.

PMID:
19666882
15.

Sexual and relationship satisfaction among persons with young-onset Parkinson's disease.

Wielinski CL, Varpness SC, Erickson-Davis C, Paraschos AJ, Parashos SA.

J Sex Med. 2010 Apr;7(4 Pt 1):1438-44. doi: 10.1111/j.1743-6109.2009.01408.x. Epub 2009 Jul 28.

PMID:
19656271
16.

Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.

Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators.

Arch Neurol. 2009 Sep;66(9):1099-104. doi: 10.1001/archneurol.2009.159. Epub 2009 Jul 13.

17.

Prominent phenotypic variability associated with mutations in Progranulin.

Kelley BJ, Haidar W, Boeve BF, Baker M, Graff-Radford NR, Krefft T, Frank AR, Jack CR Jr, Shiung M, Knopman DS, Josephs KA, Parashos SA, Rademakers R, Hutton M, Pickering-Brown S, Adamson J, Kuntz KM, Dickson DW, Parisi JE, Smith GE, Ivnik RJ, Petersen RC.

Neurobiol Aging. 2009 May;30(5):739-51. Epub 2007 Oct 18.

18.

Falls and injuries resulting from falls among patients with Parkinson's disease and other parkinsonian syndromes.

Wielinski CL, Erickson-Davis C, Wichmann R, Walde-Douglas M, Parashos SA.

Mov Disord. 2005 Apr;20(4):410-5.

PMID:
15580552
19.

Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease.

Parashos SA, Wielinski CL, Kern JA.

Clin Neuropharmacol. 2004 May-Jun;27(3):119-23.

PMID:
15190234
20.

Medical services utilization and prognosis in Parkinson disease: a population-based study.

Parashos SA, Maraganore DM, O'Brien PC, Rocca WA.

Mayo Clin Proc. 2002 Sep;77(9):918-25.

PMID:
12233925
21.

Morphological, histochemical, and interstitial pressure changes in the tibialis anterior muscle before and after aortofemoral bypass in patients with peripheral arterial occlusive disease.

Albani M, Megalopoulos A, Kiskinis D, Parashos SA, Grigoriadis N, Guiba-Tziampiri O.

BMC Musculoskelet Disord. 2002;3:8. Epub 2002 Feb 25.

22.

Ontogenetic development of the locomotor response to levodopa in the rat.

Grigoriadis N, Simeonidou C, Parashos SA, Albani M, Guiba-Tziampiri O.

Pediatr Neurol. 1996 Jan;14(1):41-5.

PMID:
8652014
23.

D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity.

Marin C, Parashos SA, Kapitzoglou-Logothetis V, Peppe A, Chase TN.

Pharmacol Biochem Behav. 1993 May;45(1):195-200.

PMID:
8516358
24.

Effect of Gi protein ADP-ribosylation induced by pertussis toxin on dopamine-mediated behaviors.

Marin C, Parashos SA, Chase TN.

Eur J Pharmacol. 1991 Mar 19;195(1):19-25.

PMID:
1676678
25.

Effect of chronic D-1 and/or D-2 dopamine antagonist treatment on SKF 38393-induced non-stereotyped grooming.

Parashos SA, Marin C, Barone P, Kapitzoglou-Logothetis V, Chase TN.

Psychopharmacology (Berl). 1990;102(3):411-3.

PMID:
2251338
26.

Dopamine D1 receptor modulation of pilocarpine-induced convulsions.

Barone P, Parashos SA, Palma V, Marin C, Campanella G, Chase TN.

Neuroscience. 1990;34(1):209-17.

PMID:
2139189
27.

Synergy between a selective D1 antagonist and a selective D2 antagonist in the induction of catalepsy.

Parashos SA, Marin C, Chase TN.

Neurosci Lett. 1989 Oct 23;105(1-2):169-73.

PMID:
2485878
28.

D-1 dopamine agonist administration reduces the threshold for convulsions produced by pilocarpine.

Barone P, Palma V, Parashos SA, Marin C, Chase TN, Campanella G.

Boll Soc Ital Biol Sper. 1989 Apr;65(4):337-41.

PMID:
2570598
29.

Haloperidol- and SCH23390-induced dopaminergic supersensitivities are not additive in the rat.

Parashos SA, Barone P, Marin CA, Paraschos AJ, Kapitzoglou-Logothetis V, Chase TN.

Psychopharmacology (Berl). 1989;98(2):189-92.

PMID:
2569216
30.
31.

[Functional interaction of dopamine receptors and chronic treatment with dopamine-antagonists].

Barone P, Tucci I, Parashos SA.

Ann Ist Super Sanita. 1988;24(4):547-50. Italian. No abstract available.

PMID:
3265291
32.

Attenuation of D-1 antagonist-induced D-1 receptor upregulation by concomitant D-2 receptor blockade.

Parashos SA, Barone P, Tucci I, Chase TN.

Life Sci. 1987 Nov 16;41(20):2279-84.

PMID:
3316889
33.

D-1 dopamine receptor changes after striatal quinolinic acid lesion.

Barone P, Tucci I, Parashos SA, Chase TN.

Eur J Pharmacol. 1987 Jun 12;138(1):141-5.

PMID:
2957219

Supplemental Content

Loading ...
Support Center